Why Do Supplement Labels Misrepresent What Ingredients They Contain?
Unlike prescription drugs, dietary supplements in the United States do not require pre-market approval from the FDA. A manufacturer can place a product on shelves and self-certify that it meets label claims. Third-party audits are voluntary, and enforcement is reactive rather than preventive.
The result is a category where independent laboratory analyses routinely find discrepancies between stated and actual ingredient concentrations. The problem is not confined to obscure brands. Studies coordinated through the National Institutes of Health Office of Dietary Supplements and testing programmes run by organisations such as NSF International have found that name-brand products can still miss their stated dose by a wide margin.
Three ingredients illustrate the problem especially well in 2026: chromium picolinate, DHEA, and vinpocetine. Each has a different reason for the mislabelling, which makes them useful case studies.
Why Is Chromium Picolinate So Often Underdosed?
Chromium picolinate is a form of the trace mineral chromium bound to picolinic acid. It is sold widely for blood-sugar management and weight loss, with label doses typically ranging from 200 to 1,000 micrograms per serving. The FDA's daily value for chromium is 35 micrograms for adult men and 25 micrograms for adult women, so label doses are already multiples of normal dietary intake.
The problem is that chromium picolinate is chemically unstable in tablet form when exposed to moisture or heat during storage. Independent testing coordinated through the NIH Office of Dietary Supplements has found products delivering as little as 40 percent of the stated dose after six months on a retail shelf. The degraded compound is not the same molecule the label describes.
There is a second issue: what ingredients manufacturers list as chromium picolinate sometimes include cheaper chromium chloride blended in. Chromium chloride has significantly lower bioavailability. Unless a product carries third-party certification such as USP or NSF, there is no public record confirming which chromium compound is actually inside.
The FDA color additive listing and the GRAS database do not cover chromium picolinate because it is not a food additive — it falls under the Dietary Supplement Health and Education Act framework, which provides less pre-market oversight. That regulatory gap is part of why the discrepancy persists.
What Makes DHEA Labels Particularly Misleading?
DHEA — dehydroepiandrosterone — is a steroid hormone produced naturally by the adrenal glands. When sold as a supplement, it is entirely synthetic: manufacturers produce it from diosgenin, a compound extracted from wild yam, through a multi-step chemical synthesis. The body cannot convert wild yam extract into DHEA on its own, so products that describe themselves as 'natural wild yam' or 'plant-based' DHEA are misrepresenting the manufacturing process.
Labelling aside, dose accuracy is a separate problem. DHEA is active at very low concentrations in the body, and the range between a physiological dose and a pharmacological one is narrow. A 2024 analysis cited by the NIH Office of Dietary Supplements found that over-the-counter DHEA products varied from 0 percent to 150 percent of the stated dose across different lots from the same brand.
Because DHEA is a hormone precursor, dose inaccuracy carries more practical consequence than it does for, say, a vitamin. Excess DHEA can convert to estrogen or testosterone in the body. The FDA has issued multiple warning letters to DHEA marketers since 2023 for unsubstantiated disease claims, and those letters are publicly searchable through openFDA enforcement records.
DHEA is also classified as a controlled substance in several countries, including Canada and the United Kingdom, which makes importation legally complex. American consumers buying internationally sourced supplements may not realise the regulatory status differs.
Is Vinpocetine Actually a Natural Supplement Ingredient?
Vinpocetine is marketed as a cognitive enhancer and is often positioned alongside herbal nootropics. Many labels describe it as derived from the periwinkle plant Vinca minor, which is technically true at the starting-material stage. However, vinpocetine itself does not exist in meaningful quantities in the plant. It is produced through chemical synthesis using vincamine, an alkaloid extracted from the plant, as a precursor.
The FDA took the position in a 2019 guidance document — and reaffirmed it through subsequent enforcement correspondence available via openFDA — that vinpocetine was investigated as a drug ingredient before it was marketed as a dietary supplement. Under DSHEA, an ingredient that was first investigated as a drug cannot be sold legally as a supplement. Despite that guidance, vinpocetine remains available in products on major retail platforms as of late 2026.
The 'is this ingredient safe' question is genuinely unsettled for vinpocetine. The FDA's concern in its guidance was not primarily about safety at typical doses but about regulatory category. Separately, the agency flagged potential risks for pregnant women based on animal reproductive toxicology data. Neither concern has resulted in a market-wide removal, partly because enforcement resources are stretched across a supplement market that generates hundreds of billions of dollars annually.
An ingredient analyzer that cross-references openFDA enforcement records will flag vinpocetine as having an active regulatory status concern — which is a meaningful signal even if the product has not been formally recalled.
How Do Manufacturers Get Away With These Discrepancies?
The short answer is that the burden of proof sits with the FDA, not with the manufacturer. The agency must demonstrate that a product is unsafe or mislabelled before it can act. That is the inverse of the drug approval system, where a manufacturer must prove safety and efficacy before sale.
Current Good Manufacturing Practice regulations for supplements, enforced by the FDA, require identity testing on incoming ingredients and finished-product testing against label specifications. But audit frequency is limited, and many smaller manufacturers use contract labs with weak verification protocols. The FDA's own inspection records, available through its warning letter database, show repeated violations for identity testing failures at supplement facilities.
Third-party certification programmes — USP, NSF International, and Informed Sport among them — do require verified testing. Products carrying those marks have a higher probability of matching label claims, though no programme is foolproof. The mark covers the tested lot, not every future production run.
What Does Third-Party Testing Actually Verify?
Third-party certification checks three things in most programmes: identity (is the ingredient what the label says it is), potency (is the dose within an acceptable tolerance, typically plus or minus 10 to 20 percent), and purity (are there heavy metals, microbes, or undisclosed pharmaceutical compounds present). A product can pass identity and fail potency, or pass both and still contain a contaminant below the programme's detection threshold.
For chromium picolinate, potency verification is the critical test. For DHEA, identity testing is essential because the synthetic route can leave residual solvents. For vinpocetine, neither potency nor purity testing addresses the core regulatory concern, which is the ingredient's legal status as a supplement.
Open Food Facts, the crowdsourced product database, has expanded its supplement tracking in 2025 and 2026 to include third-party certification status where it is disclosed on packaging. That is a useful starting point, but it reflects disclosed information — a product without a certification mark is not necessarily unsafe, and one with a mark is not automatically trustworthy across every lot.
How Can You Check What Ingredients a Supplement Actually Contains?
Start with the openFDA enforcement and warning letter database. Searching a specific ingredient name returns any formal FDA actions against products containing it. This is public, free, and updated regularly. It will not catch every mislabelled product, but it surfaces patterns quickly.
Look for a third-party certification mark and then verify it on the certifier's own website. Marks can be counterfeited or reproduced from an expired certification. NSF, USP, and Informed Sport each maintain a searchable verified product list.
An ingredient checker like InZoRAH cross-references multiple public databases — including openFDA records and Open Food Facts — and surfaces regulatory history alongside ingredient explanations. That is faster than searching each database individually, particularly if you are comparing two products on the same shelf.
Finally, check whether the ingredient has a monograph in the NIH Office of Dietary Supplements fact sheets. Those sheets summarise what the evidence says about typical doses and known risks without making product-specific claims. They are a reliable baseline before you buy.
What Should You Do If You Already Take One of These Supplements?
Do not stop abruptly without reading the physical label and, if relevant, speaking with a pharmacist or qualified health professional. That is especially true for DHEA, which acts on the hormonal system. This post is educational; it is not medical advice.
Check whether your specific product carries a third-party certification mark and verify that mark directly with the certifying organisation. If it does not carry one, search the brand name and the ingredient on the openFDA warning letter portal to see whether there is an enforcement history.
If you have concerns about an allergy or a drug interaction — DHEA in particular interacts with hormone therapies — always read the physical label and consult a health professional before making any change.
| Ingredient | Common Label Claim | Core Accuracy Problem | Regulatory Record (openFDA) |
|---|---|---|---|
| Chromium picolinate | 200–1,000 mcg per serving for blood-sugar support | Actual dose frequently 40–80% of stated amount; cheaper chromium chloride sometimes substituted | Warning letters for unsubstantiated claims; GMP violations for identity testing failures |
| DHEA | Natural wild yam; 25–100 mg per serving | Fully synthetic compound; dose varies 0–150% across lots; 'natural' framing is misleading | Warning letters for disease claims 2023–2026; controlled substance in several countries |
| Vinpocetine | Periwinkle plant extract for cognitive support | Synthetic pharmaceutical compound; FDA guidance states it cannot legally be sold as a supplement | FDA guidance 2019 reaffirmed post-2023; no market-wide removal as of November 2026 |

